Outcomes Of Repeated Administration Of Rasburicase In Recurrent Cycles For Patients With Leukemia.
Wang A, McCue D, Ravandi F et al.
Key Points:
Possibility of production of anti-rasburicase antibodies as adverse reactions in patients who received multiple cycles of rasburicase therapy.
7% of patients developed some degree of adverse reaction, including shortness of breath, chills, nausea, itching and rash.
Implications:
- Subsequent cycles of rasburicase therapy remain safe and effective.
View the original abstract on the ASH website.
